Abstract The majority of anticancer agents have a reduced or even complete loss of a therapeutic effect within hypoxic tumors
The top lipid metabolite 8-HETE (8-Hydroxyeicosatetraenoic Acid), an oxidized lipid mediator, modulates GLP1R sensitivity and signaling, influencing metabolic responses and insulin secretion dynamics 82
GLP-1 medications have substantially more long-term safety data, particularly for semaglutide which has been in widespread clinical use for over a decade across multiple indications
Unlike some prohibited substances that may enter the body inadvertently, peptides require deliberate administration
Generics for liraglutide (Saxenda) and dulaglutide (Trulicity) could be available in 2027
Therapeutic goals and patient tolerance should guide decisions, which may also be influenced by the circumstances of the healthcare system and reimbursement policies